FAQs
SMART MONEY INVESTORS
JSK Funding partners have come from top tier of bio venture capital.
INVESTORS SO FAR:
Kickstart
$325,000
State of Utah
$100,000
Cephalon $100,000
Angel $100,000
NCI Fast Track Phase one $1,070,380
NCI Phase two $2,000,000
Grant Shami $1,700,000
ARRA Supplement $2,000,000
JSK Therapeutic has been vetted by many different levels of expertise in due diligence of drug development companies.
Cephalon
Angel
Among Others
The National Cancer Institute in granting awards, Pharma companies, State Technology boards, Seed Funds and national angel investors. A partial list of committed capital follows:
NCI Fast Track Phase one $1,070,380
NCI Phase two $2,000,000
Grant Shami $1,700,000
ARRA Supplement $2,000,000
Investor FAQs
Q: Is JSK Therapeutics private?
A: Yes.
Q: How do I contact Investor Relations with a question or request?
A: Contact Joseph Nowoslawski at jfn@jskthera.com